## Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Methods</th>
<th>Participants</th>
<th>Outcomes</th>
<th>Interventions</th>
<th>Notes</th>
</tr>
</thead>
</table>
| **PROGRESS2003** | Study Type: RCT (individual) | n= 6105  
Age: Mean 64  
Sex: 4274 males 1831 females | Data Used  
Diagnosis of dementia  
MMSE | Group 1 N= 305  
Antihypertensive with - Flexible treatment regime based on perindopril 4mg/d with addition of indapamide 2.5mg/d for those whom the physician believe there was no specific indication for, nor contraindication to, the use of a diuretic. This was to maximise fall in blood pressure  
Group 2 N= 305  
Placebo with - Identical in appearance to the active agents | Study Quality: 1+  
Setting: 172 collaborating centers in 7 regions worldwide: Australia & NZ, China, France & Belgium, Italy, Japan, Sweden, UK and Republic of Ireland.  
Notes: Mean follow-up of 3.9 years  
Info on Screening Process: Not reported |
| **SCOPE2003** | Study Type: RCT (individual) | n= 4964  
Age: Mean 76  
Sex: 1780 males 3184 females | Data Used  
Major cardiovascular events | Group 1 N= 247  
Antihypertensive with - Mean dose 11.8mg - Started with 8mg candesartan once daily in the morning. If SBP remained greater than 169mmHg, or decreased by less than 10mmHg, or DBP remained greater than 85mmHg, dose was doubled  
Group 2 N= 246  
Placebo with - Matching placebo, similar in appearance and taste | Study Quality: 1++  
Setting: 527 centres in 15 countries, mainly Europe.  
Notes: No reported diagnosis  
Info on Screening Process: Not reported |
| **SHEP1991** | Study Type: RCT (individual) | n= 4736  
Age: Mean 72  
Sex: 2046 males 2690 females | Data Used  
Nonfatal and fatal stroke | Group 1 N= 237  
Placebo with - Matching placebo given in the same procedure | Study Quality: 1+  
Setting: Multicenter study. Participants stratified by clinical center and by antihypertensive medication status at initial contact.  
Notes: No reported diagnosis  
Info on Screening Process: Not reported |
References of Included Studies

PROGRESS2003
(Published Data Only)

SYST-EUR1999
Study Type: RCT (individual)
Study Description: After stratification by centre, sex and previous vascular complications, patients were randomised by means of a computerised random function.
Type of Analysis: Intention to Treat and per-protocol analysis
Blindness: Double blind
Duration (days): Mean 730
Setting: Enrolled at 106 centres from 19 European countries.
Info on Screening Process: 3162 screened, 744 excluded. Reasons: had dementia at baseline, MMSE score n/a at baseline, incomplete MMSE items, baseline MMSE <23 and did not undergo DSM-III-R.

n=2418
Age: Mean 70
Sex: 829 males 1589 females

Diagnosis:
100% No dementia

Exclusions: Diagnosis of dementia, under 60 years of age, sitting systolic blood pressure not between 160-219mmHg with diastolic blood pressure over 95mmHg, standing systolic blood pressure under 140mmHg, no informed consent, not available for long term follow-up.

Baseline: Mean (SD) blood pressure (mm Hg): Systolic - 173.2 (10.1) placebo, 173.5 (10.1) treatment. Diastolic - 86.0 (5.7) placebo, 86.1 (5.6) treatment.

Group 1 N=123
Antihypertensive with - Initiated with nitrendipine (10-40mg/day) with the poss addition of or replacement by enalapril (5-2 mg/day), hydrochlorothiazide or both drugs. Stepwise titrated & combined to reduce sitting systolic blood pressure by 20mmHg or more to less than 150mmHg.

Group 2 N=118
Placebo with - Recived matching placebo tablets.

Group 2 N=236
Antihypertensive with . Mean dose 25mg - Step 1, dose 1: chlorthalidone 12.5mg/day
Step 1, dose 2: chlorthalidone 25mg/day
Step 2, dose 1: atenolol 25mg/day
Step 2, dose 2: atenolol 50mg/day

Data Used
Diagnosis of dementia
MMSE

Setting: Community based ambulatory population in tertiary care centers.


© NCCMH. All rights reserved.